Chandler Robinson is Chief Executive Officer and Director of Monopar Therapeutics (MNPR). The company reported total compensation of $10,637,821 for fiscal year 2025.
| Salary | $700,000 |
|---|---|
| Bonus | $550,000 |
| Stock awards | $6,263,958 |
| Option awards | $2,703,862 |
| Non-equity incentive plan | $420,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $10,637,821 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Monopar Therapeutics filed April 30, 2026, accession 0001437749-26-014183.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Chandler Robinson this page | Chief Executive Officer and Director | $10,637,821 |
| Andrew Cittadine | Chief Operating Officer | $4,706,431 |
| Quan Vu | Chief Financial Officer, Secretary, and Treasurer | $2,101,314 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Monopar Therapeutics compensation brief.
Chandler Robinson's compensation sits inside Monopar Therapeutics's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.